Table 1.
Treatment regimens
| Tumor | Regimen | No. of patients (n=81) | Dose of CPT-11 (mg/m2) | Days on which CPT-11 was administered | Cycle (weeks) |
|---|---|---|---|---|---|
| Lung cancer | IP | 36 | 60 | 1, 8, 15 | 4 |
| CPT-11 monotherapy | 8 | 60 | 1, 8, 15 | 4 | |
| IP plus bevacizumab | 1 | 60 | 1, 8, 15 | 3 | |
| Colorectal cancer | IP | 1 | 130 | 1 | 3 |
| FOLFIRI | 22 | 180 | 1 | 2 | |
| FOLFIRI plus bevacizumab/cetuximab | 2 | 180 | 1 | 2 | |
| CPT-11 plus bevacizumab | 1 | 180 | 1 | 3 | |
| CPT-11, capecitabine plus bevacizumab | 1 | 180 | 1 | 2 | |
| Esophageal cancer | IP | 2 | 130 | 1 | 3 |
| FOLFIRI | 1 | 180 | 1 | 2 | |
| CPT-11 plus apatinib mesylate | 6 | 150 | 1 | 2 |
Abbreviations: CPT-11, irinotecan; IP, irinotecan plus cisplatin; FOLFIRI, folinic acid, 5-fluorouracil plus irinotecan.